<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR56">
 <label>56.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Velcheti</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Chandwani</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Pietanza</surname>
    <given-names>MC</given-names>
   </name>
   <name>
    <surname>Burke</surname>
    <given-names>T</given-names>
   </name>
  </person-group>
  <article-title>First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment</article-title>
  <source>Immunotherapy.</source>
  <year>2019</year>
  <volume>11</volume>
  <fpage>889</fpage>
  <lpage>901</lpage>
  <pub-id pub-id-type="doi">10.2217/imt-2019-0061</pub-id>
  <?supplied-pmid 31181973?>
  <pub-id pub-id-type="pmid">31181973</pub-id>
 </element-citation>
</ref>
